Signal Transduction:
ATP Hydrolysis Enhances RNA Recognition and Antiviral Signal Transduction by the Innate Immune Sensor, Laboratory of Genetics and Physiology 2 (LGP2)

Annie M. Bruns, Darja Pollpeter, Nastaran Hadizadeh, Sua Myong, John F. Marko and Curt M. Horvath

J. Biol. Chem. 2013, 288:938-946.
doi: 10.1074/jbc.M112.424416 originally published online November 26, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M112.424416

Find articles, minireviews, Reflections and Classics on similar topics on the JBC Affinity Sites.

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2012/11/26/M112.424416.DC1.html

This article cites 27 references, 13 of which can be accessed free at http://www.jbc.org/content/288/2/938.full.html#ref-list-1
ATP Hydrolysis Enhances RNA Recognition and Antiviral Signal Transduction by the Innate Immune Sensor, Laboratory of Genetics and Physiology 2 (LGP2) * S

Received for publication, October 1, 2012, and in revised form, November 20, 2012 Published, JBC Papers in Press, November 26, 2012, DOI 10.1074/jbc.M112.424416

Annie M. Bruns 1,*, Darja Pollpeter 1, Nastaran Hadizadeh 5, Sua Myong 1, John F. Marko 1,*, and Curt M. Horvath 1,2

From the Departments of 1 Molecular Biosciences and 5 Physics and Astronomy, Northwestern University, Evanston, Illinois 60208 and the 2 Institute for Genomic Biology University of Illinois, Champaign, Illinois 61801

Background: Laboratory of genetics and physiology 2 (LGP2) is a cytoplasmic RNA receptor required for innate antiviral signaling.

Results: LGP2 uses ATP hydrolysis to diversify RNA recognition and enhance antiviral signaling.

Conclusion: LGP2 mediates antiviral responses by ATP-enhanced RNA recognition.

Significance: This study reveals a novel property of LGP2 providing a mechanistic basis for its positive role in antiviral signaling.

The mammalian type I interferon (IFN) response is a powerful antiviral system that directly interferes with virus replication and contributes to both innate and adaptive immune responses. Intracellular accumulation of virus replication intermediates such as double-stranded RNA (dsRNA) or RNAs with triphosphorylated 5′-ends are detected by cytosolic pattern recognition receptors, including the CARD-helicase proteins, RIG-I-like receptor (RIG-I) 3 and MDA5. RIG-I and MDA5 recognize non-self RNAs with their C-terminal DEXD/H-box helicase domains and regulatory domains (RD) and use their N-terminal CARD regions for interactions with downstream signaling components, leading to transcriptional activation of IFN and other immediate antiviral response genes (1, 2).

A third member of the RIG-I-like receptor (RLR) family, LGP2, has significant sequence identity within the helicase domain and RD but lacks a CARD region. The functions of LGP2 in antiviral signaling have been controversial, as different experimental strategies have demonstrated seemingly antithetical biological activities. The intracellular LGP2 concentration appears to regulate a switch between positive and negative functions in antiviral signal transduction. When the protein is expressed in cells from plasmid expression vectors, LGP2 can function as a negative regulator of RLR signaling (3–5). This finding together with the observation that LGP2 expression is stimulated by virus infection led to the initial characterization of LGP2 as a feedback inhibitor of antiviral responses. In contrast, mice with a targeted disruption in the LGP2 locus are more susceptible to virus infections and have defects in antiviral IFNβ and cytokine responses. LGP2 deficiency reduces host responses to several RNA viruses including the picornaviruses encephalomyocarditis virus and poliovirus that had been previously linked to detection by MDA5 (6). The effect of LGP2 deficiency extends to innate cytokine responses triggered by cytosolic dsDNA and DNA-genome pathogens, which are impaired in cells lacking LGP2 (7). Experiments in LGP2-deficient cells also revealed a synergistic signal transduction activity resulting from co-expression of LGP2 with MDA5 (8, 9). This led to the suggestion that LGP2 may promote more efficient RNA detection by RLRs, possibly by inducing conformational alteration of viral RNAs to enable downstream recognition or by facilitating interaction between the RLRs and

* This work was supported, in whole or in part, by National Institutes of Health Grants R01AI073919 and U01AI082894 (to C. M. H.) and 1U54CA143869–01 (NU-PS-OC) and National Science Foundation Grant MCB-1022117 (to J. M.), and an Immune Mechanisms of Virus Control Pilot Award (to C. M. H. and S. M.).

This article contains supplemental Figs. S1–S4.

1 Supported in part by a predoctoral fellowship from the National Institutes of Health Cellular and Molecular Basis of Disease Training Grant T32GM008061.

2 To whom correspondence should be addressed: Pancoe Pavilion, Rm. 4401, 2200 Campus Dr., Evanston, IL 60208. Tel: 847-491-5530; Fax: 847-494-1604; E-mail: horvath@northwestern.edu.

3 The abbreviations used are: RIG-I, RIG-I-like receptor; RD, regulatory domain; RLR, RIG-I-like receptor; EMCV, encephalomyocarditis virus; LGP2, laboratory of genetics and physiology 2; AMP-PNP, adenosine 5′-(β,γ-imino)triphosphate; CARD, caspase activation and recruitment domain.
additional signaling machinery. Replacement of LGP2 with an ATP hydrolysis-inactivating helicase domain mutant results in a phenotypic copy of the LGP2 null mice, indicating that enzymatic activity is essential for LGP2 to function in the antiviral system (8). A positive antiviral role for LGP2 is also highlighted by the discovery that interferon antagonist proteins encoded by paramyxoviruses can target the LGP2 helicase domain, disrupting its ATP hydrolysis activity (10). Together, these findings are consistent with LGP2 acting as an upstream mediator of nonself RNA recognition and antiviral signaling.

ATP hydrolysis is critical for proper antiviral function of all three RLR proteins, but the role for energy utilization in their biological responses is poorly understood. Data suggesting ATP-dependent dsRNA unwinding has been reported for RIG-I (11, 12), but FRET assays failed to detect strand displacement (13); there are no reports of MDA5- or LGP2-mediated helicase activity. This uncertainty regarding the ability of RLRs to function as true RNA modifying proteins evokes a question about the exact role(s) for ATP hydrolysis in their biological functions.

A single-molecule study has demonstrated that purified RIG-I is able to translocate along RNA substrates (13). RIG-I translocation requires ATP, and the rate is increased when the dsRNA substrate contains a 5′-triphosphate (5′-PPP) modification. The ability of RIG-I to translocate along dsRNA without unwinding the duplex has been suggested to be an exclusive function of RLR proteins (14). However, the generality of dsRNA translocation as a property of MDA5 and LGP2, and the important question of the biological significance of RNA translocation in RLR-mediated antiviral signaling have not yet been addressed.

In this study biochemical and biophysical approaches were used to conduct a quantitative evaluation of the enzymatic and RNA binding properties of LGP2. The results reveal that LGP2 possesses high basal ATP hydrolysis activity that can be mutagenically distinguished from dsRNA-stimulated ATP hydrolysis. Moreover, experimental evidence demonstrates that LGP2 utilizes this basal ATP hydrolysis to enhance and diversify its RNA recognition capacity. The consequence of this ATP-dependent phenomenon is revealed in antiviral signaling assays demonstrating that synergistic activation of MDA5-mediated IFNβ production by LGP2 requires ATP hydrolysis. These findings define a previously unrecognized ATP-dependent RNA sensing property of LGP2 and provide a mechanistic basis for its upstream antiviral signal transduction activity.

**EXPERIMENTAL PROCEDURES**

**Plasmids and Recombinant Baculovirus**—FLAG-tagged RIG-I and RIG-I-C cDNA was cloned into the baculovirus transfer vector pBac2cp (Novagen). FLAG-tagged LGP2 cDNA was cloned into the pVL-1393 transfer vector (BD Biosciences). Site-directed mutagenesis was carried out using QuikChangeXL mutagenesis (Stratagene). Mutations introduced to generate the LGP2 motif mutants were confirmed by DNA sequencing. The baculovirus transfer vector containing the cDNA of interest was co-transfected with linearized baculovirus DNA (BD Biosciences) into SF9 insect cells grown in SF900-II (Invitrogen) supplemented with 1% penicillin/streptomycin (Invitrogen) and 10% fetal bovine serum (Invitrogen). Homologous recombination generated a baculovirus expressing RIG-I, RIG-I-C, LGP2, or LGP2 mutant proteins. These baculoviruses were amplified in SF9 cells three times, for 3 days each, reaching a titer of $\sim 1 \times 10^8$ pfu/ml quantified by plaque assay. Virus stocks were stored in the dark at 4 °C.

**Protein Expression and Purification**—SF9 cells were infected with recombinant baculovirus (1 pfu/cell) for 4 days, then cell lysates were prepared in whole cell extract buffer (50 mM Tris, pH 8.0, 280 mM NaCl, 0.5% IGEPAL, 0.2 mM EDTA, 10% glycerol, 1 mM DTT) supplemented with protease inhibitor mixture (Roche Applied Science) and 200 mM Na$_2$VO$_3$. Lysates were pre-cleared with Sepharose 6B beads (Sigma), and the FLAG-tagged proteins were then immunoaffinity purified with anti-FLAG M2 affinity beads (Sigma). Immunoprecipitated proteins were eluted with 150 μg/ml of 3× FLAG peptide, and quantified by Bradford assay (27). The purity of the proteins was assessed by SDS-PAGE and Coomassie Blue staining. Spectrophotometric measurement of the 260:280 nm absorbance ratios revealed no nucleic acid contamination with values ranging from 0.47 to 0.65.

**ATP Hydrolysis Assays**—ATP hydrolysis assays were completed using the Enz-Check Phosphate Assay Kit (Molecular Probes) according to the manufacturer’s protocol with 100 nM protein concentrations and 500 μM ATP, unless otherwise noted. The ATP hydrolysis rate is calculated based on the slope of a standard curve generated in parallel for each assay and is expressed in nanomoles of ATP hydrolyzed per minute per milligram of protein (nmol of ATP min$^{-1}$ μg$^{-1}$). The nonhydrolyzable ATP analogue AMP-PNP was from Sigma (A2647), and ADP-AlF$_4$ was made by incubating 10 mM ADP (Sigma A2754), 50 mM NaF (Sigma S7920), and 10 mM AlCl$_3$ (Sigma 563919). $V_{max}$, $K_m$, and $k_{cat}$ were calculated according to standard Michaelis-Menten enzyme kinetics, using the initial rates of ATP hydrolysis for the indicated protein at ATP concentrations between 50 and 1000 μM. All ATP hydrolysis assays completed to obtain enzymatic efficiency were conducted using 150 nM protein concentration.

**Flow Cell Preparation and Single Molecule Microscopy**—Flow cells for single molecule observations were created by coating a microscope slide with polyethylene glycol (PEG, $M_w \approx 5000$, Laysan Bio) and a coverslip with 98% PEG and 2% PEG-biotin (Laysan Bio). The coverslip and slide are assembled to create individual chambers incubated with neutravidin followed by the biotinylated dsRNA substrate. RNA substrates were imaged in T-50 buffer (10 mM Tris-HCl, pH 7.5, 3 mM MgCl$_2$, and 50 mM NaCl) containing an oxygen scavenging system (1 mg/ml of glucose oxidase (Sigma), 0.04 mg/ml of catalase (Sigma), and 0.4% dextrose) to reduce photobleaching, and 1% β-mercaptoethanol (Acros) serving as a triplet state quencher. The prepared flow cell was placed on a heated objective at 37 °C for imaging using a Olympus IX81 TIRF microscope ($\times$100/1.45 NA objective), ImageEM EMCCD camera (Hamamatsu), and 561 nm (75 milliwatts) laser (Melles Griot). Image acquisition was done using Slidebook software (Olympus) capturing one frame per 100 ms for 2 min. Protein/ATP was diluted as indicated in imaging buffer and added to the flow cell immediately before image capture.
RNA Substrates—All RNA substrates were ordered from Integrated DNA Technology (IDT) modified with a 3′ Cy3 fluorophore, or a 3′ biotin tag. The fluoroceinely labeled strand (RNA 3′-Cy3) was used for all substrates. The biotinylated strand was either completely complementary or contained additional nucleotides to create the series of bulged substrates depicted in Fig. 3. Each single molecule experiment with LGP2 ± ATP and the imperfect dsRNA substrates was done in parallel with the standard dsRNA substrate within different chambers of the same flow cell. This enables all four conditions to be tested (bulged dsRNA with 80 nm LGP2, bulged dsRNA with 80 nm LGP2 and 500 μM ATP, dsRNA with 80 nm LGP2, and dsRNA with 80 nm LGP2 and 500 μM ATP) with minimized concern for effects due to batch-to-batch variability in flow cell preparation. The RNA sequences used to create all duplexes were: RNA 3′-Cy3, 5′-GCAGAGGGUCGUCGCACGACGCGC-3′; dsRNA, biotin-3′-CGUCUCUCCACCGCACGAGGGCUCCACGAGUGGCUGUUCG-5′; 3 top bulge, biotin-3′-CGUCUCUCCACCGCACGAGGGCUCCACGAGUGGCUGUUCG-5′; 3 bottom bulge, biotin-3′-CGUCUCUCCACCGCACGAGGGCUCCACGAGUGGCUGUUCG-5′; 3 bulge, biotin-3′-CGUCUCUCCACCGCACGAGGGCUCCACGAGUGGCUGUUCG-5′; 6 bulge, biotin-3′-CGUCUCUCCACCGCACGAGGGCUCCACGAGUGGCUGUUCG-5′; 17 bulge, biotin-3′-CGUCUCUCCACCGCACGAGGGCUCCACGAGUGGCUGUUCG-5′; 3 double bulge, biotin-3′-CGUCUCUCCACCGCACGAGGGCUCCACGAGUGGCUGUUCG-5′; triple bulge, biotin-3′-CGUCUCUCCAGACCCCGAGGGCUCCACGAGUGGCUGUUCG-5′.

Data Analysis—Following data acquisition, a custom written spot-identifying computer program was used to select fluorescence “spots” (i.e., RNA substrates) based on their individual fluorescence intensity, and their separation from other fluorophores (supplemental Fig. S1a). This program then generates fluorescence intensity time trajectories (“traces”) for individual molecules and classifies fluorescence intensities as a function of time as level 0, bleached fluorophore; level 1, RNA alone; level 2, RNA with protein bound; or level 0, bleached fluorophore. The accuracy of this spot-identifying computer program was used to select fluorophores (supplemental Fig. S1a).

Luciferase Reporter Gene Assays—Human embryonic kidney cell line HEK293T were seeded in 24-well tissue culture plates, and cotransfected with Lipofectamine 2000 (Invitrogen) with the reporter gene and expression vectors for Renilla luciferase along with a plasmid containing the indicated helicase. The reporter gene contains the firefly luciferase open reading frame under the control of the −110 IFNβ promoter. The concentration of MDA5 plasmid was held constant at 50 ng/well, and the amount of LGP2 or LGP2 mutant plasmid was varied at 5, 10, and 50 ng/well. The following day cells were infected with EMCV Mengo strain at multiplicity of infection = 3, or transfected with 5 μg/ml of poly(I:C) using Lipofectamine 2000 for 8 h before harvesting. Relative luciferase activity was measured using Dual Luciferase™ reporter assay (Promega). Data are plotted as the average of triplicate samples with error bars representing S.D. The data presented are representative of three independent experiments.

RESULTS

LGP2 Has Both Basal and dsRNA-activated ATP Hydrolysis Activity—The ATP hydrolysis kinetics were quantitatively compared for both LGP2 and RIG-I (Fig. 1A). RIG-I exhibits very low ATP hydrolysis activity in the absence of dsRNA, and is activated by the addition of poly(I:C), reaching an ATP hydrolysis rate of 1.173 ± 0.175 nmol of ATP min−1 mg−1 (Table 1). Addition of poly(I:C) stimulates the enzyme efficiency of RIG-I (Kcat/Km) from 0.08 ± 0.1 to 0.64 ± 0.6 min−1 μM−1 (Table 2). In contrast to the dsRNA-inducible enzymatic activity of RIG-I, LGP2 exhibits a high ATP hydrolysis activity even in the absence of poly(I:C), with a basal rate of 393 ± 48 nmol of ATP min−1 mg−1, and a Kcat/Km of 0.27 ± 0.03 min−1 μM−1. The addition of poly(I:C) increases the rate of LGP2 ATP hydrolysis to 766 ± 31 nmol of ATP min−1 mg−1, whereas the Kcat/Km does not change significantly at 0.23 ± 0.02 min−1 μM−1 (Tables 1 and 2). This indicates that whereas the catalytic efficiency of RIG-I is greatly enhanced by poly(I:C) stimulation, the efficiency of LGP2 is similar in the presence and absence of poly(I:C). This analysis also defines two enzymatic activities of LGP2: basal dsRNA-independent ATP hydrolysis and dsRNA-stimulated ATP hydrolysis.

Single Molecule Analysis of LGP2 RNA Binding—A single molecule imaging assay was used to quantitatively evaluate the RNA binding properties of LGP2 (13). Fluorescently labeled dsRNA substrates are tethered to a glass slide and incubated with purified RLR proteins. Protein binding increases the fluorescence intensity of the bound dsRNA molecule via a phenomenon referred to as protein-induced fluorescence enhancement, or PIFE (13, 15). RNA association, dissociation, and translocation can be observed and measured using TIRF microscopy to monitor the intensity of a single fluorophore over time. The data output consists of individual traces corresponding to the fluorescence intensity of a single RNA molecule over time (supplemental Figs. S1 and S2). Measurements were made in parallel chambers of a dsRNA-coated slide to minimize effects due to variability in slide preparation. The interactions of an RLR with RNA substrates can thereby be analyzed with or without ATP, at different concentrations, or under distinct buffer conditions.

Analysis of these experiments revealed two apparent RNA populations. One population of RNA molecules featured LGP2 binding and unbinding, whereas the other did not exhibit binding by LGP2. The population of RNA molecules that interacted with LGP2 displayed highly reproducible dwell times in the bound or unbound state. Due to their consistent behavior, only traces containing at least one binding or unbinding event were
ATP-enhanced RNA Recognition and Signaling by LGP2

used to calculate binding kinetics, whereas the non-interacting population was not included in the calculation. From the bound RNAs, histograms of the dwell times in the bound or unbound state were generated. These histograms were then fit to the exponential decay form $y = y_0 e^{-kt}$, determining $k$ as an on rate for histograms of unbound dwell times, or off rate for histograms of bound dwell times. These rates were then used to calculate the $K_d$ as $(k_{off}/k_{on}) \times [protein]$ (supplemental Fig. S1).

As a positive control, the binding and translocation of a RIG-I protein lacking the N-terminal CARDs (RIG-I-C) was evaluated. In the absence of ATP, RIG-I-C bound to the 25-bp dsRNA with a $K_d$ of 98 ± 13 nm, similar to the previously reported 76.3 nm (13). In the presence of ATP RIG-I-C translocation was observed with an average period ($\Delta t$) of 4.0 s at 50 μM ATP in agreement with the reported $\Delta t$ of 3.7 s at 60 μM ATP (13) (supplemental Fig. S2).

In the absence of ATP, LGP2 was calculated to have a $K_d$ of 50 ± 5 nm (Table 3, data analysis as described in supplemental Fig. S1), but in the presence of ATP, RNA translocation by LGP2 was not observed under conditions permissive for RIG-I-C translocation. RNA binding experiments using various LGP2 preparations, ATP concentrations, or buffer conditions did not reveal LGP2 translocation. Instead, a different behavior of LGP2 was observed in single-molecule analysis in the presence of ATP. Analysis of 80 nM LGP2 protein without ATP resulted in only 30 ± 3% of all dsRNAs with at least one binding event, leaving the majority of RNA molecules in the unbound population. In parallel analysis, 50 μM ATP combined with 80 nM LGP2 increased the number of LGP2-associated dsRNAs to 51.5 ± 2%, whereas 500 μM ATP resulted in 69 ± 3.5% of RNA molecules bound by LGP2 (Fig. 1b, n = 3). Higher concentrations of ATP did not result in a significant increase in the fraction of RNA molecules able to be recognized by LGP2. To rule out effects resulting from batch-to-batch variation in flow cell preparation, adjacent chambers of the same flow cell were used to compare samples with and without ATP side-by-side. Over the course of eight separate experiments with 80 nM LGP2, the presence of 500 μM ATP resulted in an average 30 ± 7% increase in the number of RNA molecules able to be bound, compared with parallel experiments conducted in the absence of ATP.

In one representative experiment, in the absence of ATP, 1,005 total traces were analyzed from five separate fields of view and only 374 (37%) had observable binding events, but in the presence of 500 μM ATP, 926 total analyzed traces contained 646 with observable binding events (70%). Moreover, the presence of ATP resulted in more robust and dynamic LGP2-dsRNA interactions, increasing the number of binding events per molecule from 1.1 ± 0.3 to 1.7 ± 0.34 events per 120-s (1200 frame) trace (Fig. 1c). These results indicate that ATP dramatically enhances the ability of LGP2 to recognize RNA.

**ATP Hydrolysis Is Required for Enhanced RNA Recognition by LGP2** Nonhydrolyzable ATP analogues were used in both single molecule and biochemical assays to determine whether the enhanced recognition requires ATP hydrolysis. Both ADP-AIF₄ and AMP-PNP reduced the rate of ATP hydrolysis when used in a competition experiment (Fig. 1d, Table 1). When added to 100 μM ATP, 100 μM AMP-PNP decreased the rate of ATP hydrolysis from 304 ± 27 to 154 ± 15 nmol of ATP min⁻¹ mg⁻¹, and 100 μM ADP-AIF₄ decreased the rate to 190 ± 17 nmol of ATP min⁻¹ mg⁻¹ (Table 1). In single molecule analysis, neither nonhydrolyzable analogue was sufficient to enhance LGP2 dsRNA binding, and the addition of equimolar ATP and
ATP-enhanced RNA Recognition and Signaling by LGP2

**TABLE 1**

<table>
<thead>
<tr>
<th>Protein</th>
<th>Poly(I:C)</th>
<th>ATP</th>
<th>Non-hydrolyzable ATP analogue</th>
<th>Rate of ATP hydrolysis (±S.D.)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>LGP2</td>
<td>0 µg/ml</td>
<td>500 µM</td>
<td></td>
<td>393 ± 48 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td></td>
<td>2.5 µg/ml</td>
<td></td>
<td></td>
<td>474 ± 44 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td></td>
<td>5 µg/ml</td>
<td></td>
<td></td>
<td>502 ± 25 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td></td>
<td>25 µg/ml</td>
<td></td>
<td></td>
<td>605 ± 33 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td></td>
<td>50 µg/ml</td>
<td></td>
<td></td>
<td>766 ± 31 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td></td>
<td>100 µg/ml</td>
<td>500 µM</td>
<td></td>
<td>800 ± 16 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td></td>
<td>50 µg/ml</td>
<td>100 µM</td>
<td>AMP-PNP</td>
<td>531 ± 34 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td></td>
<td>50 µg/ml</td>
<td>100 µM</td>
<td>ADP-AIF₄</td>
<td>304 ± 27 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td></td>
<td>50 µg/ml</td>
<td>100 µM</td>
<td>ADP-AIF₄</td>
<td>154 ± 15 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td>LGP2</td>
<td>50 µg/ml</td>
<td></td>
<td>AMP-PNP</td>
<td>190 ± 17 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td>RIG-I</td>
<td>0 µg/ml</td>
<td>500 µM</td>
<td></td>
<td>65 ± 15 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td></td>
<td>25 µg/ml</td>
<td></td>
<td>AMP-PNP</td>
<td>52 ± 14 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td></td>
<td>0 µg/ml</td>
<td>500 µM</td>
<td></td>
<td>75 ± 11 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td>No protein</td>
<td>0 µg/ml</td>
<td>500 µM</td>
<td></td>
<td>1173 ± 175 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td></td>
<td>5 µg/ml</td>
<td></td>
<td>AMP-PNP</td>
<td>41 ± 13 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td></td>
<td>5 µg/ml</td>
<td></td>
<td>AMP-PNP</td>
<td>38 ± 15 nmol min⁻¹ mg⁻¹</td>
</tr>
</tbody>
</table>

a Values are the average of at least two independent experiments shown ±S.D.

**TABLE 2**

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Vmax</th>
<th>Km</th>
<th>kcat</th>
<th>kat</th>
<th>kcal/Km</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>µmol/min</td>
<td>µM</td>
<td>min⁻¹</td>
<td>M⁻¹</td>
<td></td>
</tr>
<tr>
<td>LGP2</td>
<td>3.2 ± 0.5</td>
<td>78 ± 6.0</td>
<td>21.5 ± 2.1</td>
<td>0.27 ± 0.03</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5.6 ± 0.6</td>
<td>160 ± 8.5</td>
<td>37.4 ± 3.7</td>
<td>0.23 ± 0.02</td>
<td></td>
</tr>
<tr>
<td>LGP2 MIIa</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>LGP2 K651E</td>
<td>3.2 ± 0.5</td>
<td>78 ± 6.0</td>
<td>21.5 ± 2.1</td>
<td>0.27 ± 0.03</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5.6 ± 0.6</td>
<td>160 ± 8.5</td>
<td>37.4 ± 3.7</td>
<td>0.23 ± 0.02</td>
<td></td>
</tr>
<tr>
<td>RIG-I</td>
<td>1.5 ± 0.4</td>
<td>121 ± 9.0</td>
<td>101 ± 1.9</td>
<td>0.08 ± 0.01</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.8 ± 0.9</td>
<td>187 ± 8.2</td>
<td>120 ± 4.8</td>
<td>0.64 ± 0.06</td>
<td></td>
</tr>
<tr>
<td>RIG-1/C</td>
<td>7.8 ± 0.7</td>
<td>102 ± 6.6</td>
<td>52 ± 4.1</td>
<td>0.51 ± 0.05</td>
<td></td>
</tr>
<tr>
<td></td>
<td>14 ± 1.0</td>
<td>235 ± 9.4</td>
<td>94 ± 5.0</td>
<td>0.40 ± 0.06</td>
<td></td>
</tr>
</tbody>
</table>

a Poly(I:C) was used at 50 µM/ml.

b Values are the average of at least two independent experiments shown ±S.D.

Mutagenesis of LGP2 Distinguishes Basal and dsRNA-stimulated ATP Hydrolysis—To further investigate the relationship between enzymatic activity and RNA binding, LGP2 mutations were designed to target key amino acids involved in ATP binding, ATP hydrolysis, or RNA binding (Fig. 2A). The LGP2 mutant MI targets the Walker A motif and lacks ATP hydrolysis but retains RNA binding (16–19). Mutant MIII is defective for both ATP hydrolysis and RNA binding (16). Three other LGP2 mutations were designed to target residues that available structural information indicated might be important for biological activity (20–23). LGP2 mutant MIIa targets a lysine and a tyrosine (K138E, Y142F) conserved in RIG-I and LGP2 motif IIA (21–23). LGP2 mutant N461I targets a conserved asparagine that mediates dsRNA binding interactions in the RIG-I crystal structure (23). LGP2 mutant K651E was based on the observation that mutation of LGP2 lysine 651 to glutamic acid completely disrupts RNA recognition by the isolated C-terminal RD (20).

The enzymatic activity and RNA binding properties of these five mutants were measured and compared with wild type LGP2 (Fig. 2, Table 3). In agreement with previous observations (16), LGP2 mutant MI was defective for ATP hydrolysis but bound dsRNA with an affinity similar to wild type, whereas mutant MIII was defective for both ATP hydrolysis and RNA binding. Both mutant MIIa and K651E displayed measurable but decreased dsRNA affinity (335 ± 70 and 462 ± 28 nm, respectively). LGP2 mutant N461I was able to bind dsRNA similarly to wild type (Kd = 53 ± 8 nm).

Analysis of the ATP hydrolysis activities revealed that none of the mutants retained basal ATP hydrolysis (Fig. 2B, black bars), but addition of poly(I:C) stimulated ATP hydrolysis by two of the LGP2 mutants to nearly wild type levels (MIIa to 530 ± 33 nmol of ATP min⁻¹ mg⁻¹ and K651E to 543 ± 20 nmol of ATP min⁻¹ mg⁻¹; see Fig. 2B and Table 3). The addition of poly(I:C) also significantly increased their catalytic efficiency (Table 2). These mutant proteins display only dsRNA-stimulated ATP hydrolysis and not basal ATP hydrolysis, providing tools to investigate the importance of basal ATP hydrolysis in LGP2 RNA binding.

**Basal ATP Hydrolysis Enhances LGP2 RNA Binding**—Single-molecule experiments were performed to test the LGP2 mutants’ RNA binding properties in the absence or presence of ATP (Fig. 2C). In these experiments 500 µM ATP induced a 30% average increase in the number of molecules bound by wild type LGP2, but all of the mutants showed no increased RNA recognition in the presence of ATP, irrespective of their ability to hydrolyze ATP. Although LGP2 mutants MIIa and K651E retained their dsRNA-stimulated ATP hydrolysis activity, they failed to exhibit ATP-enhanced RNA binding (Fig. 2C). These results indicate that basal, rather than dsRNA-stimulated, enzymatic activity is required for enhanced RNA recognition by LGP2.

**ATP Increases Substrate Recognition Capacity of LGP2**—Although the role of LGP2 in antiviral defense is not completely resolved, studies of LGP2-deficient mice have been interpreted to indicate it may function upstream of MDA5 and RIG-I to remodel RNA or enhance RNA recognition (8, 10, 24). Analysis of the single-molecule RNA binding data suggested that ATP hydrolysis may allow LGP2 increased access to heterogeneous dsRNA species within the population. To directly test this hypothesis, a series of imperfect dsRNA substrates were designed that contain 3–7 nucleotide noncomplementary bulges at defined positions (Fig. 3A). These bulged RNAs are progressively poorer substrates for LGP2 recognition when compared with the standard complementary dsRNA (Fig. 3A).
The RNAs with the greatest modification (6 bulge, 7 bulge) displayed no detectable binding above background (Fig. 3A, ND). When these modified substrates were tested in the presence and absence of ATP, the observed effect of ATP hydrolysis-mediated enhancement of RNA recognition by LGP2 was even more pronounced. A single example from a representative experiment with the RNA substrate referred to as the “3 top bulge” is displayed in Fig. 3B. In the absence of ATP, significantly fewer of the modified substrates are recognized by LGP2 in comparison to the standard dsRNA substrate. However, in the presence of ATP the percentage of modified substrates recognized by LGP2 is almost identical to the observed recognition of the standard dsRNA substrates.

To compare the ATP-dependent increase in the number of dsRNA molecules recognized without concern for slight differences in flow cell preparation or general experimental variation, each bulged substrate was analyzed in individual chambers of the same flow cell with or without ATP in parallel with the dsRNA substrate. For each individual experiment the percent of standard dsRNA molecules recognized by LGP2 in the absence of ATP is set equal to 1 (Fig. 3C). Each bulged substrate displays reduced recognition by LGP2 in the absence of ATP, producing values lower than 1. In the presence of ATP, LGP2 recognizes the bulge-modified substrates and the complementary dsRNA substrates similarly. These results indicate that ATP hydrolysis increases LGP2 interactions with intrinsically poor dsRNA substrates, and accommodates heterogeneity that is present in a population of dsRNAs.

The RNA binding and ATP hydrolysis rates of LGP2 and mutants

<table>
<thead>
<tr>
<th>Protein</th>
<th>$K_d$ with dsRNA ± S.D.*</th>
<th>Basal ATP hydrolysis (0 µg/ml) of poly(I:C) ± S.D.†</th>
<th>dsRNA-stimulated ATP hydrolysis (5 µg/ml) of poly(I:C) ± S.D. ‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>LGP2</td>
<td>50 ± 5 nm</td>
<td>363 ± 9 nmol min⁻¹ mg⁻¹</td>
<td>592 ± 25 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td>LGP2 MII</td>
<td>57 ± 11 nm</td>
<td>48 ± 17 nmol min⁻¹ mg⁻¹</td>
<td>55 ± 11 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td>LGP2 MIIa</td>
<td>335 ± 70 nm</td>
<td>33 ± 10 nmol min⁻¹ mg⁻¹</td>
<td>530 ± 33 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td>LGP2 MII</td>
<td>ND</td>
<td>62 ± 13 nmol min⁻¹ mg⁻¹</td>
<td>37 ± 9 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td>LGP2 K651E</td>
<td>462 ± 28 nm</td>
<td>41 ± 12 nmol min⁻¹ mg⁻¹</td>
<td>543 ± 20 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td>LGP2 N461I</td>
<td>53 ± 8 nm</td>
<td>41 ± 13 nmol min⁻¹ mg⁻¹</td>
<td>43 ± 14 nmol min⁻¹ mg⁻¹</td>
</tr>
<tr>
<td>No protein</td>
<td>ND</td>
<td>38 ± 15 nmol min⁻¹ mg⁻¹</td>
<td></td>
</tr>
</tbody>
</table>

*Values are the average of at least two independent experiments shown ± S.D.
† All experiments were conducted at 500 µM ATP.
‡ ND, not detected.

To compare the ATP-dependent increase in the number of dsRNA molecules recognized without concern for slight differences in flow cell preparation or general experimental variation, each bulged substrate was analyzed in individual chambers of the same flow cell with or without ATP in parallel with the dsRNA substrate. For each individual experiment the percent of standard dsRNA molecules recognized by LGP2 in the absence of ATP is set equal to 1 (Fig. 3C). Each bulged substrate displays reduced recognition by LGP2 in the absence of ATP, producing values lower than 1. In the presence of ATP, LGP2 recognizes the bulge-modified substrates and the complementary dsRNA substrates similarly. These results indicate that ATP hydrolysis increases LGP2 interactions with intrinsically poor dsRNA substrates, and accommodates heterogeneity that is present in a population of dsRNAs.

LGP2 Requires ATP Hydrolysis to Potentiate MDA5-mediated IFNβ Production—Previous studies have suggested that LGP2 may work in conjunction with MDA5 to mediate antiviral signaling and IFNβ production (8, 24). The single-molecule experiments presented here indicate that LGP2 uses the energy from ATP hydrolysis to increase its interactions with a more diverse range of dsRNA substrates. The biological impact of this ATP-dependent RNA recognition was tested in an antiviral signaling assay in which LGP2 or mutant LGP2 was titrated into MDA5-dependent IFNβ promoter transcription assays. MDA5 is constitutively active in this assay and can activate the IFNβ promoter when expressed, irrespective of infection with encephalomyocarditis virus (EMCV) or transfection with poly(I:C) (Fig. 4) (16, 25). Introducing low levels of wild type LGP2 is synergistic with MDA5 and results in a 2-fold increase in IFNβ promoter activity (Fig. 4A and supplemental Fig. S3). Raising the level of LGP2 expression reduces the MDA5-dependent IFNβ promoter activity, consistent with the reported feedback inhibition effect of LGP2 expression (3–5). To test if ATP hydrolysis is required for synergistic MDA5-mediated IFNβ promoter activity, two LGP2 mutants were co-transfected at a range of plasmid concentrations. LGP2 MII is defective for both basal and RNA-stimulated ATP hydrolysis,
whereas LGP2 MIIa lacks basal ATP hydrolysis, but retains RNA-stimulated ATP hydrolysis. Unlike wild type LGP2, neither of these mutants is able to enhance MDA5-mediated signaling at low expression levels, but both display the inhibitory activity of LGP2 at higher expression levels (Fig. 4B and supplemental Fig. S3). Parallel analysis of all the LGP2 mutants defective for ATP hydrolysis verified that none of the mutant proteins were able to enhance MDA5-mediated signaling (Fig. 4C), demonstrating that intact ATP hydrolysis is critical for LGP2 to stimulate MDA5 signal transduction responses.

**DISCUSSION**

The cytosolic innate pattern recognition receptors, RIG-I and MDA5, are thought to scan the cytoplasm for RNA signatures indicative of virus infection. Identification of non-self RNA triggers activation of downstream antiviral responses through protein interactions mediated by their CARD regions. Due to the absence of these signaling domains in LGP2, its role in upstream activation of antiviral signaling was not initially apparent, but analysis of mice lacking LGP2 expression indicated that LGP2 was required for the optimal detection of and response to RNA virus infections in vivo (8, 9). The present studies demonstrate that LGP2 is capable of using energy derived from ATP hydrolysis to enhance its ability to associate with diverse dsRNA species, enabling it to act in concert with MDA5 to maximize antiviral signal transduction. These results provide a unique mechanistic basis for an ATP-dependent function of LGP2 in promoting signal transduction in response to intracellular virus infections.

All of the RLRs require ATP hydrolysis for their biological activity in the antiviral system. LGP2 uses basal ATP hydrolysis to enhance association with the dsRNA species but RIG-I, the archetypal RLR, does not hydrolyze ATP in the absence of dsRNA. When bound to dsRNA, RIG-I can use ATP to power translocation, presumably to scan the molecule for its preferred molecular signature, 5’-end triphosphorylation (13), which locks it in an active signaling configuration (26). The exact roles for ATP hydrolysis in MDA5 biological activity remain to be determined, but like RIG-I, it does not hydrolyze ATP in the absence of dsRNA. When bound to dsRNA, RIG-I can use ATP to power translocation, presumably to scan the molecule for its preferred molecular signature, 5’-end triphosphorylation (13), which locks it in an active signaling configuration (26). The results presented here demonstrate that LGP2 is distinct in its ability to hydrolyze ATP in the absence of dsRNA, and that dsRNA-independent basal ATP hydrolysis and dsRNA-dependent hydrolysis can be separated by site-directed mutagenesis. Moreover, analysis of these mutant proteins indicates that basal, but not dsRNA-dependent, ATP hydrolysis is required for enhanced recognition of dsRNA species by LGP2.
A role for LGP2 in the initial phase of RNA virus detection is consistent with reports that it is essential for responses to diverse pathogen-associated molecular patterns and pathogens including dsRNA and RNA viruses (8, 9), dsDNA and DNA viruses, and the intracellular bacterium, *Listeria monocytogenes* (7). Cellular responses to many virus types that have been linked previously to RIG-I, such as vesicular stomatitis virus and Sendai virus, were impaired in the absence of LGP2, and picornaviruses including EMCV, poliovirus, and Mengo virus, were highly sensitive to LGP2 deficiency (8). This led to the conclusion that LGP2 may function upstream of other RLRs to facilitate pattern recognition and subsequent antiviral signal transduction (8, 10, 24). The observed ATP-enhanced dsRNA interaction mediated by LGP2 provides a biochemical means to explain the effects of LGP2 on RLR RNA recognition. This is supported by the inability of ATP hydrolysis-defective mutants to enhance MDA5-mediated IFNβ gene expression. This phenomenon also accounts for the fact that an ATPase-defective LGP2 protein fails to compensate for LGP2 deficiency in mice (8). Furthermore, naturally occurring paramyxovirus-encoded immune evasion proteins target both MDA5 and LGP2, but not RIG-I. These LGP2 inhibitors bind to the helicase domain and interfere specifically with ATP hydrolysis activity (10), underscoring the importance of enzymatic activity in LGP2 function.

Clearly ATP hydrolysis by LGP2 is required for antiviral responses *in vivo*, but this does not exclude the possibility of a feedback inhibitory role for LGP2 that is regulated by its intracellular concentration. At low levels, LGP2 was found to be a positive regulator of IFNβ signaling, but at higher concentrations LGP2 functions as a negative regulator. 

![Figure 4](https://example.com/figure4.png)

**FIGURE 4.** LGP2 ATP hydrolysis is required for enhanced MDA5-mediated IFNβ signaling. A, HEK293T cells were transfected with a −110 IFNβ-luciferase reporter gene, control Renilla luciferase plasmid, and expression vectors for the indicated helicase proteins MDA5 or LGP2. MDA5 was transfected at a constant 25 ng of plasmid/well, whereas the amount of LGP2 transfected varied at 0.03, 0.16, 0.8, 4, 20, 100, and 500 ng. Following a 24-h transfection, cells were transfected with 5 μg/ml of poly(I:C) (left) or infected with 3 pfu/cell EMCV (right) for 8 h before harvesting. At low concentrations LGP2 enhances MDA5-mediated IFNβ signaling, but at higher concentrations LGP2 functions as a negative regulator. B, HEK293T cells were transfected with a −110 IFNβ-luciferase reporter gene, control Renilla luciferase plasmid, and expression vectors for the indicated helicase proteins MDA5, LGP2 MII, or LGP2 MIIa mutants. MDA5 was transfected at a constant 25 ng of plasmid/well, whereas the amount of LGP2 transfected varied at 0.03, 0.16, 0.8, 4, 20, 100, and 500 ng. Following a 24-h transfection, cells were transfected with 5 μg/ml of poly(I:C) for 8 h before harvesting. Neither LGP2 MII nor LGP2 MIIa are able to enhance MDA5-mediated signaling. C, HEK293T cells were transfected with a −110 IFNβ-luciferase reporter gene, control Renilla luciferase plasmid, and expression vectors for the indicated helicase proteins MDA5, LGP2, or LGP2 mutants. MDA5 was transfected at a constant 50 ng of plasmid/well, whereas the amount of LGP2 transfected was varied at 5 (white), 10 (gray), and 50 ng (black) of plasmid. Following a 24-h transfection, cells were infected with 3 pfu/cell EMCV or transfected with 5 μg/ml of poly(I:C) for 8 h before harvesting. None of the ATP hydrolysis defective mutants are able to enhance MDA5-mediated signaling.

In summary, these data indicate that LGP2 uses intrinsic RNA-independent ATP hydrolysis activity to increase its RNA recognition repertoire and enhance cooperative activation of RLR signaling. The exact nature of this cooperation is currently a matter of speculation (24), but may involve several mechanisms including but not limited to allowing more efficient...
engagement of RLRs with diverse substrates that are present during virus infections, alteration of RNA secondary and tertiary structures, displacement of proteins from ribonucleoprotein complexes, or alteration in the subcellular localization of RNAs and RLRs. It is predicted that the ATP hydrolysis-mediated enhanced RNA recognition by LGP2 will form a common basis for functions of this RLR protein in mediating antiviral defenses to specific pathogens in distinct physiological or cellular contexts in vivo.

Acknowledgments—We are grateful to members of the Horvath and Marko laboratories for critical comments and helpful discussions.

REFERENCES